Obsidian Therapeutics Inc.(OBX)

Biotechnology · Cambridge, MA

$13.59-0.25 (-1.81%)

Delayed quote: Oct 6, 2026, 1:30 PM EDT

Price/FCF Ratio: N/A

Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.

The Price/FCF ratio is N/A as of 2026-10-06T17:33:22.553Z.

Stored calculation inputs

Calculation as of: 2026-10-06T17:33:22.553Z.

Quote observation: 2026-10-06T17:30:09.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 14,135,231
TTM free cash flow: N/A

FMP input reference: 0fde8dae4c5ae63ee7b35c7e6e46bba2fdf5d6d5db310b32cf0eb41a7e17e840

P/E Ratio|FCF Growth|Operating Margin|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

OBX Price/FCF Ratio Metrics

PRICE/FCF RATIO

N/A

OBX Competitors' Price/FCF Ratio

OBX

Obsidian Therapeutics Inc.

Current

Market Cap

$14.14M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PLSM

Pulsenmore Ltd. Ordinary Shares

vs OBX

Market Cap

$14.11M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

HIND

Vyome Holdings, Inc.

vs OBX

Market Cap

$13.62M

Price/FCF Ratio

25.96

TTM Avg

28.16

3Y Avg

28.16

5Y Avg

28.16

SINT

Sintx Technologies, Inc.

vs OBX

Market Cap

$13.66M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CTXR

Citius Pharmaceuticals, Inc.

vs OBX

Market Cap

$13.55M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

KTTA

Pasithea Therapeutics Corp.

vs OBX

Market Cap

$14.87M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

OPTH

Optimi Health Corp.

vs OBX

Market Cap

$13.36M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

INAB

IN8bio, Inc.

vs OBX

Market Cap

$13.35M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

COCP

Cocrystal Pharma, Inc.

vs OBX

Market Cap

$15.24M

Price/FCF Ratio

N/A

TTM Avg

82.38

3Y Avg

82.38

5Y Avg

82.38

CLRB

Cellectar Biosciences, Inc.

vs OBX

Market Cap

$12.62M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	PRICE/FCF RATIO	TTM	3Y	5Y
Obsidian Therapeutics Inc. (OBX)	$14.14M	N/A	N/A	N/A	N/A
Pulsenmore Ltd. Ordinary Shares (PLSM)vs ›	$14.11M	N/A	N/A	N/A	N/A
Vyome Holdings, Inc. (HIND)vs ›	$13.62M	25.96	28.16	28.16	28.16
Sintx Technologies, Inc. (SINT)vs ›	$13.66M	N/A	N/A	N/A	N/A
Citius Pharmaceuticals, Inc. (CTXR)vs ›	$13.55M	N/A	N/A	N/A	N/A
Pasithea Therapeutics Corp. (KTTA)vs ›	$14.87M	N/A	N/A	N/A	N/A
Optimi Health Corp. (OPTH)vs ›	$13.36M	N/A	N/A	N/A	N/A
IN8bio, Inc. (INAB)vs ›	$13.35M	N/A	N/A	N/A	N/A
Cocrystal Pharma, Inc. (COCP)vs ›	$15.24M	N/A	82.38	82.38	82.38
Cellectar Biosciences, Inc. (CLRB)vs ›	$12.62M	N/A	N/A	N/A	N/A

Free Cash Flow Valuation

P/FCF Ratio

N/A

FCF Yield

N/A

Price/FCF Ratio Formula & Definition

P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Price/FCF Ratio: N/A

OBX Price/FCF Ratio Metrics

OBX Competitors' Price/FCF Ratio

Free Cash Flow Valuation

Price/FCF Ratio Formula & Definition

Related Metrics